Search

Displaying results 6511 - 6520 of 9705 in total
  1. Drug

    S-8510

    go.drugbank.com/drugs/DB06504
    Experimental

    S-8510 / SB-737552 is a BZD inverse agonist investigated for the treatment of Alzheimer’s disease and mild to moderate senile dementia. It was being codeveloped by Shionogi and GlaxoSmithKline.

  2. Drug

    MLN2704

    go.drugbank.com/drugs/DB06513
    Investigational

    A Phase 1/2 trial (NCT00070837) evaluated the safety, dosage, and pharmacokinetics of MLN2704 in patients with metastatic androgen-independent prostate cancer.

  3. Drug

    Astaxanthin

    go.drugbank.com/drugs/DB06543
    Investigational

    Astaxanthin is a keto-carotenoid in the terpenes class of chemical compounds. It is classified as a xanthophyll but it is a carotenoid with no vitamin A activity. … It may be found in fish feed or some animal food as a color additive.

    Mixtures: VitaHealth L-Glutathione Plus
  4. Drug

    MG98

    go.drugbank.com/drugs/DB06544
    Experimental

    MG98, a second-generation antisense oligodeoxynucleotide inhibitor of human DNMT1, was investigated in the completed clinical trial NCT00003890 for treating patients with advanced solid tumors.

  5. Drug

    Bivatuzumab

    go.drugbank.com/drugs/DB06550
    Investigational

    Bivatuzumab (previously BIWA 4) is a humanized monoclonal antibody against CD44 v6. [A31688,A31689]

  6. Drug

    Pascolizumab

    go.drugbank.com/drugs/DB06560
    Investigational

    Pascolizumab (SB 240683) is a humanized anti-interleukin-4 antibody with therapeutic potential in asthma.

  7. Drug

    Agomelatine

    go.drugbank.com/drugs/DB06594
    ApprovedInvestigational

    Agomelatine is a potent agonist at melatonin receptors and an antagonist at serotonin-2C (5-HT2C) receptors, tested in an animal model of depression.

    Products: AGOMELATIN AL 25MG FTA
  8. Drug

    Midostaurin

    go.drugbank.com/drugs/DB06595
    ApprovedInvestigational

    Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. … It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hematopoietic tumors [A19108].

    Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index
  9. Drug

    Lexatumumab

    go.drugbank.com/drugs/DB06599
    Investigational

    Lexatumumab is a fully humanized, high-affinity immunoglobulin G(1 lambda) monoclonal antibody (mAb).

  10. Drug

    Reslizumab

    go.drugbank.com/drugs/DB06602
    ApprovedInvestigational

    Asthma is a chronic respiratory disease that causes inflammation in the lungs with asthma attacks that lead to severe breathing difficulties. … In addition, a significant improvement in lung function was seen, as measured by the volume of air exhaled by patients in one second [L1133].